Johnson & Johnson COVID-19 vaccine trial paused due to 'unexplained illness'


Johnson & Johnson on Monday night announced that it has paused its COVID-19 vaccine trial due to one of the volunteers coming down with an "unexplained illness."
In a statement, Johnson & Johnson said that under its guidelines, the "participant's illness is being reviewed and evaluated" by the study's independent data safety monitoring board (DSMB), as well as internal clinical and safety physicians. The company also said that "adverse events — illnesses, accidents, etc. — even those that are serious, are an expected part of any clinical study, especially large studies."
Johnson & Johnson's vaccine arm, Janssen, began the Phase 3 clinical trial in September. There are 60,000 participants, and each person is receiving one dose of the vaccine. Advanced clinical trials are conducted so researchers can determine whether participants are experiencing side effects, and Johnson & Johnson said it is not revealing what illness the volunteer has due to privacy reasons.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Dr. Ashish Jha, dean of the Brown University School of Public Health, told CNN that the pause is "completely expected" due to how large the study is, and this is "just a reminder how ridiculous it is to try and meet a political timeline of having a vaccine before Nov. 3." Jha added that it is important for the vaccine to be "safe and we've got to let the process play out and it's going to take a while. To me, it's reassuring that companies are acting responsibly and pausing when they need to."
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
The Assassin: action-packed caper is 'terrific fun'
The Week Recommends Keeley Hawes stars as a former hitwoman drawn out of retirement for 'one last job'
-
The EPA wants to green-light approval for a twice-banned herbicide
Under the radar Dicamba has been found to harm ecosystems
-
Crossword: July 30, 2025
The Week's daily crossword
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year
-
Economists fear US inflation data less reliable
speed read The Labor Department is collecting less data for its consumer price index due to staffing shortages
-
Crypto firm Coinbase hacked, faces SEC scrutiny
Speed Read The Securities and Exchange Commission has also been investigating whether Coinbase misstated its user numbers in past disclosures
-
Starbucks baristas strike over dress code
speed read The new uniform 'puts the burden on baristas' to buy new clothes, said a Starbucks Workers United union delegate
-
Warren Buffet announces surprise retirement
speed read At the annual meeting of Berkshire Hathaway, the billionaire investor named Vice Chairman Greg Abel his replacement